Budesonide Inhaler Market 2022 to cross US$ 8.24 Billion with 5.8% CAGR by 2027 | Pfizer Inc., Cipla Limited,

Budesonide Inhaler Market – Insights

Budesonide is a medication that is used to prevent symptoms of asthma. It is a corticosteroid or steroid (cortisone-like medicine). The medication prevents inflammation in the lungs to reduce the severity of asthma attack. Inhaled budesonide may be used with other asthma medicines such as bronchodilators, which are used to open up narrowed breathing passages in the lungs. Budesonide is available in several forms such as powders, suspensions, and tablets. In powder form, the medication can be inhaled by mouth using an inhaler. In suspension form, it is inhaled by mouth, using a special jet nebulizer (machine that turns medication into a mist, which can be inhaled). Some of the trade names under which budesonide is sold include Pulmicort, Rhinocort, and Entocort.

The global budesonide inhaler market was valued at US$ 5.25 billion in 2017 and is expected to exhibit a CAGR of 5.8% over the forecast period (2018-2026).

Increasing number of launches in generic version of budesonide inhaler is expected to drive growth of the budesonide inhaler market

Increasing number of launches in generic version of budesonide inhaler is a major driving factor, which is expected to drive growth of the budesonide inhaler market growth over the forecast period. For instance, in 2016, Nephron Pharmaceuticals Corporation (Nephron) launched generic Budesonide Inhalation Suspension in the U.S. Nephron has licensed the Abbreviated New Drug Application from Apotex, Inc. Budesonide inhalation suspension is the generic version of Pulmicort Respules that is manufactured by AstraZeneca LP. Nephron is responsible for manufacturing, marketing, and distribution of Budesonide.

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐚𝐧𝐝 𝐆𝐞𝐭 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐅𝐅

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 @ https://www.coherentmarketinsights.com/promo/buynow/2551

Budesonide Inhaler Market - Restraints

The major restraining factor for budesonide inhaler market growth include side effects exhibited by budesonide such as runny or stuffy nose, sneezing, coughing, sore throat, dry throat, nosebleed, nausea, vomiting, diarrhea, stomach pain, white patches or sores inside the mouth or on lips, headache, hoarseness, voice changes, or bad taste in the mouth. For instance, according to the Product Monograph of Pulmicort Turbuhaler from AstraZeneca Canada Inc. of 2017, side effects can be observed in 2 to 4% population, who are under the treatment of Pulmicort Turbuhaler (budesonide). Some adverse effects include respiratory infection, rhinitis, ear infection, otitis media, and viral infection, which can be observed in less than 3% population.

Budesonide Inhaler Market - Regional Insights

On the basis of region, the global budesonide inhaler market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global budesonide inhaler market over the forecast period, owing to increasing regulatory approvals of budesonide inhaler. For instance, in November 2017, Cipla Ltd. received final approval for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL from the U.S. Food and Drug Administration (FDA) to market a generic version of AstraZeneca's Pulmicort Respules. It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.

𝐓𝐨 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐂𝐨𝐯𝐢𝐝𝟏𝟗 𝐈𝐦𝐩𝐚𝐜𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 @ https://www.coherentmarketinsights.com/insight/request-sample/2551

Asia Pacific is expected to witness a rapid growth in the budesonide inhaler market during the forecast period. This is attributed to the presence of major companies such as Cipla Limited, Lupin Limited, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Lunan Better Pharmaceutical, Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd. in emerging economies such as China, India, and Japan.

Budesonide Inhaler Market - Competitive Landscape

Major Key Players in Markets are 𝗣𝗳𝗶𝘇𝗲𝗿 𝗜𝗻𝗰., 𝗖𝗶𝗽𝗹𝗮 𝗟𝗶𝗺𝗶𝘁𝗲𝗱, 𝗟𝘂𝗽𝗶𝗻 𝗟𝗶𝗺𝗶𝘁𝗲𝗱, 𝗖𝗼𝘀𝗺𝗼 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀, 𝗧𝗮𝗸𝗲𝗱𝗮 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗟𝘁𝗱., 𝗠𝗮𝗻𝘂𝘀 𝗔𝗸𝘁𝘁𝗲𝘃𝗮 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗟𝗟𝗣, 𝗔𝗯𝗯𝗼𝘁𝘁 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀, 𝗟𝘂𝗻𝗮𝗻 𝗕𝗲𝘁𝘁𝗲𝗿 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹, 𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗚 (𝗦𝗮𝗻𝗱𝗼𝘇), 𝗠𝘆𝗹𝗮𝗻 𝗡.𝗩., 𝗦𝗸𝘆𝗲𝗽𝗵𝗮𝗿𝗺𝗮, 𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮 𝗣𝗹𝗰., 𝗖𝗵𝗶𝗲𝘀𝗶 𝗙𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗶 𝗦.𝗽.𝗔, 𝗢𝗿𝗶𝗼𝗻 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗶𝗼𝗻, 𝗦𝗮𝗻𝘁𝗮𝗿𝘂𝘀 𝗜𝗻𝗰., 𝗦𝘆𝗻𝗺𝗼𝘀𝗮 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗦𝗵𝗮𝗻𝗴𝗵𝗮𝗶 𝗦𝗶𝗻𝗲 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀 𝗖𝗼. 𝗟𝘁𝗱.

Detailed Segmentation:

• Global Budesonide Inhaler Market, By Product Type:

o Inhalants
o Nebulizer

• Global Budesonide Inhaler Market, By Dosage:

o Aerosols
o Dry Powder
o Suspension
o Spray

• Global Budesonide Inhaler Market, By Strength:

o 0.25 mg
o 0.5 mg
o 1.0 mg

• Global Budesonide Inhaler Market, By Distribution Channel:

o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐚𝐧𝐝 𝐆𝐞𝐭 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐅𝐅

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 @ https://www.coherentmarketinsights.com/promo/buynow/2551

Contact Us:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About US:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.